493 related articles for article (PubMed ID: 23481700)
21. Cyclin-dependent kinaselike 5 is a novel target of immunotherapy in adult T-cell leukemia.
Kawahara M; Hori T; Matsubara Y; Okawa K; Uchiyama T
J Immunother; 2007; 30(5):499-505. PubMed ID: 17589290
[TBL] [Abstract][Full Text] [Related]
22. Ligandomes obtained from different HLA-class II-molecules are homologous for N- and C-terminal residues outside the peptide-binding cleft.
Kampstra ASB; van Heemst J; Janssen GM; de Ru AH; van Lummel M; van Veelen PA; Toes REM
Immunogenetics; 2019 Sep; 71(8-9):519-530. PubMed ID: 31520135
[TBL] [Abstract][Full Text] [Related]
23. The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy.
Neidert MC; Kowalewski DJ; Silginer M; Kapolou K; Backert L; Freudenmann LK; Peper JK; Marcu A; Wang SS; Walz JS; Wolpert F; Rammensee HG; Henschler R; Lamszus K; Westphal M; Roth P; Regli L; Stevanović S; Weller M; Eisele G
Acta Neuropathol; 2018 Jun; 135(6):923-938. PubMed ID: 29557506
[TBL] [Abstract][Full Text] [Related]
24. Increased diversity of the HLA-B40 ligandome by the presentation of peptides phosphorylated at their main anchor residue.
Marcilla M; Alpízar A; Lombardía M; Ramos-Fernandez A; Ramos M; Albar JP
Mol Cell Proteomics; 2014 Feb; 13(2):462-74. PubMed ID: 24366607
[TBL] [Abstract][Full Text] [Related]
25. Naturally processed non-canonical HLA-A*02:01 presented peptides.
Hassan C; Chabrol E; Jahn L; Kester MG; de Ru AH; Drijfhout JW; Rossjohn J; Falkenburg JH; Heemskerk MH; Gras S; van Veelen PA
J Biol Chem; 2015 Jan; 290(5):2593-603. PubMed ID: 25505266
[TBL] [Abstract][Full Text] [Related]
26. The structural basis of HLA-associated drug hypersensitivity syndromes.
Pompeu YA; Stewart JD; Mallal S; Phillips E; Peters B; Ostrov DA
Immunol Rev; 2012 Nov; 250(1):158-66. PubMed ID: 23046128
[TBL] [Abstract][Full Text] [Related]
27. Nonclassical HLA-G molecules are classical peptide presenters.
Diehl M; Münz C; Keilholz W; Stevanović S; Holmes N; Loke YW; Rammensee HG
Curr Biol; 1996 Mar; 6(3):305-14. PubMed ID: 8805247
[TBL] [Abstract][Full Text] [Related]
28. Abundance, Betweenness Centrality, Hydrophobicity, and Isoelectric Points Are Relevant Factors in the Processing of Parental Proteins of the HLA Class II Ligandome.
Lorente E; Martín-Galiano AJ; Kadosh DM; Barriga A; García-Arriaza J; Mir C; Esteban M; Admon A; López D
J Proteome Res; 2022 Jan; 21(1):164-171. PubMed ID: 34937342
[TBL] [Abstract][Full Text] [Related]
29. HLA class I molecules consistently present internal influenza epitopes.
Wahl A; Schafer F; Bardet W; Buchli R; Air GM; Hildebrand WH
Proc Natl Acad Sci U S A; 2009 Jan; 106(2):540-5. PubMed ID: 19122146
[TBL] [Abstract][Full Text] [Related]
30. HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL).
Kowalewski DJ; Schuster H; Backert L; Berlin C; Kahn S; Kanz L; Salih HR; Rammensee HG; Stevanovic S; Stickel JS
Proc Natl Acad Sci U S A; 2015 Jan; 112(2):E166-75. PubMed ID: 25548167
[TBL] [Abstract][Full Text] [Related]
31. A comprehensive analysis of peptides presented by HLA-A1.
Giam K; Ayala-Perez R; Illing PT; Schittenhelm RB; Croft NP; Purcell AW; Dudek NL
Tissue Antigens; 2015 Jun; 85(6):492-6. PubMed ID: 25880248
[TBL] [Abstract][Full Text] [Related]
32. Toward a definition of self: proteomic evaluation of the class I peptide repertoire.
Hickman HD; Luis AD; Buchli R; Few SR; Sathiamurthy M; VanGundy RS; Giberson CF; Hildebrand WH
J Immunol; 2004 Mar; 172(5):2944-52. PubMed ID: 14978097
[TBL] [Abstract][Full Text] [Related]
33. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes.
Buzyn A; Ostankovitch M; Zerbib A; Kemula M; Connan F; Varet B; Guillet JG; Choppin J
Eur J Immunol; 1997 Aug; 27(8):2066-72. PubMed ID: 9295046
[TBL] [Abstract][Full Text] [Related]
34. Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation.
Bassani-Sternberg M; Pletscher-Frankild S; Jensen LJ; Mann M
Mol Cell Proteomics; 2015 Mar; 14(3):658-73. PubMed ID: 25576301
[TBL] [Abstract][Full Text] [Related]
35. HSPVdb--the Human Short Peptide Variation Database for improved mass spectrometry-based detection of polymorphic HLA-ligands.
Nijveen H; Kester MG; Hassan C; Viars A; de Ru AH; de Jager M; Falkenburg JH; Leunissen JA; van Veelen PA
Immunogenetics; 2011 Mar; 63(3):143-53. PubMed ID: 21125265
[TBL] [Abstract][Full Text] [Related]
36. Immunodominance among EBV-derived epitopes restricted by HLA-B27 does not correlate with epitope abundance in EBV-transformed B-lymphoblastoid cell lines.
Crotzer VL; Christian RE; Brooks JM; Shabanowitz J; Settlage RE; Marto JA; White FM; Rickinson AB; Hunt DF; Engelhard VH
J Immunol; 2000 Jun; 164(12):6120-9. PubMed ID: 10843661
[TBL] [Abstract][Full Text] [Related]
37. Extraordinary cross-reactivity of an autoimmune T-cell receptor recognizing specific peptides both on autologous and on allogeneic HLA class II molecules.
Hansen BE; Rasmussen AH; Jakobsen BK; Ryder LP; Svejgaard A
Tissue Antigens; 2007 Jul; 70(1):42-52. PubMed ID: 17559580
[TBL] [Abstract][Full Text] [Related]
38. What Is the Role of HLA-I on Cancer Derived Extracellular Vesicles? Defining the Challenges in Characterisation and Potential Uses of This Ligandome.
Boyne C; Lennox D; Beech O; Powis SJ; Kumar P
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948350
[TBL] [Abstract][Full Text] [Related]
39. Artificial antigen-presenting cells expressing HLA class II molecules as an effective tool for amplifying human specific memory CD4(+) T cells.
Garnier A; Hamieh M; Drouet A; Leprince J; Vivien D; Frébourg T; Le Mauff B; Latouche JB; Toutirais O
Immunol Cell Biol; 2016 Aug; 94(7):662-72. PubMed ID: 26924643
[TBL] [Abstract][Full Text] [Related]
40. Unbiased Characterization of Peptide-HLA Class II Interactions Based on Large-Scale Peptide Microarrays; Assessment of the Impact on HLA Class II Ligand and Epitope Prediction.
Wendorff M; Garcia Alvarez HM; Østerbye T; ElAbd H; Rosati E; Degenhardt F; Buus S; Franke A; Nielsen M
Front Immunol; 2020; 11():1705. PubMed ID: 32903714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
